DK172954B1 - Lægemiddel med antitumorvirkning samt fremgangsmåder til fremstilling deraf - Google Patents

Lægemiddel med antitumorvirkning samt fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK172954B1
DK172954B1 DK198703931A DK393187A DK172954B1 DK 172954 B1 DK172954 B1 DK 172954B1 DK 198703931 A DK198703931 A DK 198703931A DK 393187 A DK393187 A DK 393187A DK 172954 B1 DK172954 B1 DK 172954B1
Authority
DK
Denmark
Prior art keywords
hexadecylphosphocholine
optionally
weight
drug
mixture
Prior art date
Application number
DK198703931A
Other languages
Danish (da)
English (en)
Other versions
DK393187A (da
DK393187D0 (da
Inventor
Hansjoerg Eibl
Original Assignee
Max Planck Gesellschaft
Chaften E V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Chaften E V filed Critical Max Planck Gesellschaft
Publication of DK393187A publication Critical patent/DK393187A/da
Publication of DK393187D0 publication Critical patent/DK393187D0/da
Application granted granted Critical
Publication of DK172954B1 publication Critical patent/DK172954B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK198703931A 1985-12-04 1987-07-28 Lægemiddel med antitumorvirkning samt fremgangsmåder til fremstilling deraf DK172954B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE3542893 1985-12-04
DE3542893 1985-12-04
DE3606631 1986-02-28
DE3606631 1986-02-28
EP8600705 1986-12-04
PCT/EP1986/000705 WO1987003480A2 (en) 1985-12-04 1986-12-04 Medicament with anti-tumoral action containing hexadecylphosphocholine

Publications (3)

Publication Number Publication Date
DK393187A DK393187A (da) 1987-07-28
DK393187D0 DK393187D0 (da) 1987-07-28
DK172954B1 true DK172954B1 (da) 1999-10-18

Family

ID=25838509

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198703931A DK172954B1 (da) 1985-12-04 1987-07-28 Lægemiddel med antitumorvirkning samt fremgangsmåder til fremstilling deraf
DK398587A DK398587A (da) 1985-12-04 1987-07-30 Antitumorvirksomt laegemiddel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK398587A DK398587A (da) 1985-12-04 1987-07-30 Antitumorvirksomt laegemiddel

Country Status (15)

Country Link
US (2) US4837023A (enExample)
EP (4) EP0248047B1 (enExample)
JP (2) JPH0637393B2 (enExample)
AT (2) ATE64529T1 (enExample)
CA (2) CA1338627C (enExample)
DE (4) DE3641491A1 (enExample)
DK (2) DK172954B1 (enExample)
ES (2) ES2038215T3 (enExample)
FI (2) FI873363A7 (enExample)
GR (2) GR3002487T3 (enExample)
HU (2) HU208143B (enExample)
IE (2) IE59777B1 (enExample)
NO (2) NO174877C (enExample)
PT (2) PT83872B (enExample)
WO (2) WO1987003478A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
DE69026991T2 (de) * 1989-08-10 1997-01-16 Sandoz Ag Phospholipide zur Behandlung der multiplen Sklerose
US5182271A (en) * 1989-08-10 1993-01-26 Sandoz Ltd. Thioether, keto-ester and alkyl phospholipids useful in treating multiple sclerosis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
ATE158295T1 (de) * 1991-07-04 1997-10-15 Asta Medica Ag Verfahren zur herstellung von alkylphosphocholinen und reinherstellung derselben
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
CA2164717C (en) * 1993-06-10 2009-10-20 Louis S. Kucera Method of combatting hepatitis b virus infection
EP0717631B1 (en) 1993-09-09 2003-07-09 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
JP4259611B2 (ja) * 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
WO1996024598A1 (en) * 1995-02-10 1996-08-15 The University Of British Columbia [4-hexadecyl-3-methoxy-butyl] phosphonic acid and its protein conjugates useful as anti-cancer agents
KR19980703088A (ko) 1995-03-16 1998-09-05 라카일레 지, 필리페 신규의 침전탄산칼슘 안료를 포함하는 잉크젯 기록지
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) * 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
DK1051159T3 (da) * 1998-01-22 2002-08-05 Zentaris Ag Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CN1486289A (zh) * 2001-05-29 2004-03-31 皇家菲利浦电子有限公司 金属-陶瓷的结合
KR100871648B1 (ko) * 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
EP1962862B1 (en) 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
JP2011057647A (ja) * 2009-09-14 2011-03-24 Adeka Corp 化粧料
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
CN102491994B (zh) * 2011-12-07 2014-10-15 宁波九胜创新医药科技有限公司 一种胆碱磷酸烷基酯的制备方法
ES2860823T3 (es) * 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225227A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Derivate des n.n-bis-(2-chlor-aethyl)-phosphorsaeureamids
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法

Also Published As

Publication number Publication date
FI873363L (fi) 1987-08-03
DE19375061I2 (de) 2008-11-20
DE3641491A1 (de) 1987-09-17
HUT44441A (en) 1988-03-28
NO174877B (no) 1994-04-18
GR3005168T3 (enExample) 1993-05-24
NO174877C (no) 1994-07-27
EP0248062A1 (de) 1987-12-09
IE59777B1 (en) 1994-04-06
WO1987003478A3 (en) 1987-09-24
EP0248062B1 (de) 1992-05-06
PT83873B (pt) 1989-01-17
WO1987003480A2 (en) 1987-06-18
US4837023A (en) 1989-06-06
IE863177L (en) 1987-06-04
WO1987003478A2 (en) 1987-06-18
DK398587D0 (da) 1987-07-30
DK393187A (da) 1987-07-28
ATE75608T1 (de) 1992-05-15
EP0230575A2 (de) 1987-08-05
NO873243D0 (no) 1987-08-03
CA1280369C (en) 1991-02-19
DE3679908D1 (de) 1991-07-25
PT83872B (pt) 1989-01-17
HU203201B (en) 1991-06-28
HU208143B (en) 1993-08-30
NO175620B (enExample) 1994-08-01
PT83873A (de) 1987-01-01
DK393187D0 (da) 1987-07-28
JPH0637393B2 (ja) 1994-05-18
JP2857084B2 (ja) 1999-02-10
US5049552A (en) 1991-09-17
CA1338627C (en) 1996-10-01
FI873364A0 (fi) 1987-08-03
FI873364A7 (fi) 1987-08-03
FI873363A0 (fi) 1987-08-03
PT83872A (de) 1987-01-01
ES2038215T3 (es) 1993-07-16
JPH0859677A (ja) 1996-03-05
EP0225608A2 (de) 1987-06-16
NO873243L (no) 1987-10-02
IE59778B1 (en) 1994-04-06
NO873244L (no) 1987-10-01
HUT44431A (en) 1988-03-28
FI873363A7 (fi) 1987-08-03
EP0248047A1 (de) 1987-12-09
DE3641379A1 (de) 1987-09-03
EP0248047B1 (de) 1991-06-19
ES2032755T3 (es) 1993-03-01
EP0230575A3 (de) 1987-12-02
NO175620C (no) 1994-11-09
DK398587A (da) 1987-07-30
IE863176L (en) 1987-06-04
ATE64529T1 (de) 1991-07-15
WO1987003480A3 (en) 1988-02-25
JPS63501719A (ja) 1988-07-14
NO873244D0 (no) 1987-08-03
GR3002487T3 (en) 1992-12-30
EP0225608A3 (de) 1987-10-28

Similar Documents

Publication Publication Date Title
DK172954B1 (da) Lægemiddel med antitumorvirkning samt fremgangsmåder til fremstilling deraf
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE3042117A1 (de) Gynosaponine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
CN109771431A (zh) 和厚朴酚衍生物的新用途
KR19980703829A (ko) 바이러스 및 암 성장 억제용, 엔-클로로페닐카르바메이트및 엔-클로로페닐티오카르바메이트 함유 약학 조성물
US20160120887A9 (en) Tumor eradication by inositol-tripyrophosphate
US20060241086A1 (en) Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
US4068003A (en) Method of medical treatment of myasthenia
AU709068B2 (en) Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
US6309674B1 (en) Therapeutic agents for respiratory diseases
KR20170014005A (ko) 13가지 글리세리드를 포함한 의이인오일, 제제 및 그 응용
US6254879B1 (en) Methods of treating protozoal diseases
US6475520B1 (en) Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation
US5916884A (en) Compositions containing a mixture of phosphorus compounds and alkylglycerols
EP3777852B1 (en) Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
EP1513539B1 (de) Verwendung von amphiphilen nucleosid-phosphonoameisensäure-derivaten zur behandlung von viralen infektionskrankheiten
DD281961A5 (de) Verfahren zur herstellung eines antitumorwirksamen arzneimittels
US20020173489A1 (en) Compositions containing a mixture of phosphorous compounds and alkylglycerols
JPH01211528A (ja) 抗ｈｉｖ剤
KR20170031146A (ko) 13가지 글리세리드를 포함한 약물조성물, 제제 및 그 응용
CN112569213A (zh) 大麻二酚在制备治疗急性b淋巴细胞白血病的药物中的应用
JPS62187410A (ja) Ａｔｐ増強組成物
MXPA99009817A (es) Composiciones farmaceuticas de arglabina y derivados de arglabina.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired